Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sophiris Bio Inc SPHS

Healthcare Biotechnology
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is... see more

Recent & Breaking News (EXPM:SPHS)

Sophiris Bio to Present at the Jefferies 2014 Global Healthcare Conference

Business Wire May 22, 2014

Sophiris Enters into Common Stock Purchase Agreement with Aspire Capital to Support Proof of Concept Study of PRX302 in Prostate Cancer

Business Wire May 19, 2014

Sophiris Bio Reports First Quarter Financial Results

Business Wire May 13, 2014

Sophiris Bio to Present at the 13th Annual Needham Healthcare Conference

Business Wire March 25, 2014

Sophiris Adds Gerald T. Proehl to its Board of Directors

Business Wire March 20, 2014

Sophiris Bio Reports Fourth Quarter and Full Year 2013 Financial Results and Key Operational Highlights

Business Wire March 13, 2014

Sophiris Bio to Present at the Cowen and Company 34th Annual Health Care Conference

Business Wire February 26, 2014

Sophiris Bio to Present at the 2014 Leerink Global Healthcare Conference

Business Wire February 3, 2014

Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights

Business Wire November 12, 2013

Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights

Canada NewsWire November 12, 2013

Sophiris Bio Applies for Voluntary Delisting from TSX

Business Wire November 5, 2013

Sophiris Announces First Patients Dosed in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Business Wire October 28, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on AVNR, SGNT, SPHS and WLK

Accesswire September 12, 2013

Sophiris Bio to Present at the Stifel Healthcare Conference

Canada NewsWire September 5, 2013

IIROC Trade Resumption - SHS

Canada NewsWire August 16, 2013

IIROC Trade Resumption - Sophiris Bio Inc.

Newsfile August 16, 2013

Sophiris Bio Prices its Previously Announced Public Offering of Common Shares

Canada NewsWire August 16, 2013

IIROC Trade Halt - Sophiris Bio Inc.

Newsfile August 16, 2013

IIROC Trading Halt - SHS

Canada NewsWire August 16, 2013

Sophiris Bio Announces Share Consolidation

Canada NewsWire August 12, 2013